Add Yahoo as a preferred source to see more of our stories on Google. Dr. Deephak Swaminath and his team at Medical Center Hospital were the first in West Texas to use the Pulse Select PFA (pulsed ...

A novel pulsed field ablation technology was safe and prevented atrial arrhythmia recurrence in most patients with paroxysmal ...

Dr. Deephak Swaminath and his team at Medical Center Hospital were the first in West Texas to use the Pulse Select PFA (pulsed field ablation) system. Pulse Select PFA is an emerging and newer, ...

Pulse Biosciences (NASDAQ:PLSE) said it is sharpening its focus on its nanosecond pulsed field ablation platform for atrial ...

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...

Treatment success with pulsed field ablation was higher at 1 year than with antiarrhythmic drug therapy for patients with persistent atrial fibrillation.

Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.

In patients with persistent atrial fibrillation, those receiving pulsed field ablation as first-line therapy had less risk ...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced ...

CellFX marks another route for Afib ablation technology ...

Detailed price information for Pulse Biosciences CS (PLSE-Q) from The Globe and Mail including charting and trades.

Durable volume reduction was demonstrated with an average volume reduction of 74% of treated benign thyroid nodules at 15-22 months post-treatment. Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of ...